Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

By W. Alhazzani, M. Møller, Y. Arabi, M. Loeb, M. Gong, E. Fan, S. Oczkowski, Mitchell M. Levy, L. Derde, A. Dzierba and 26 more. Critical Care Medicine, 2020

2,417 citations recorded by the source corpus.

Supplemental Digital Content is available in the text. Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. Methods: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. Results: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy. Conclusion: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines.

Subfields: Epidemiology, Infectious Diseases, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a17525ba0365d376469cb2e8faeb0bad6d6ed682

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Busana
2. L. Brazzi
3. P. Caironi
4. F. Romitti

Citations in the corpus

• Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. (2020, neutral): “Median (IQR) 18 (10-23) 17 (12-24) 15 (12-21)”
• COVID-19 pneumonia: different respiratory treatments for different phenotypes? (2020, background): “The Surviving Sepsis Campaign panel recently recommended that "mechanically ventilated patients with COVID-19 should be managed similarly to other patients with acute respiratory failure in the ICU [1] .”
• COVID-19 and multisystem inflammatory syndrome in children and adolescents (2020, neutral): “17,113 Because some patients might have severe myocardial dysfunction, caution is needed to avoid fluid overload.”